Skip to search formSkip to main contentSkip to account menu

OM 8980

Known as: OM-8980 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryA total of 95 patients suffering from active rheumatoid arthritis were included in this double-blind, placebo-controlled… 
1994
1994
OM-8980 is a slow-acting antirheumatic drug (SAARD). It is a glycoprotein extract of Escherichia coli, with immunomodulatory… 
1993
1993
Sixty patients with active RA were evaluated over 6 months in a double-blind randomized dose range multicentre study comparing… 
Review
1993
Review
1993
  • T. Vischer
  • Clinical and Experimental Rheumatology
  • 1993
  • Corpus ID: 13573637
The results obtained with Subreum®, a peptide extract of E. coli, given orally, as a slow acting antirheumatic drug are… 
Review
1993
Review
1993
  • D. Trentham
  • Current Opinion in Rheumatology
  • 1993
  • Corpus ID: 26433919
Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the… 
1991
1991
OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the… 
1990
1990
  • T. Vischer
  • Clinical Rheumatology
  • 1990
  • Corpus ID: 29963168
SummaryA 6-month double-blind study of OM-8980 and auranofin in 145 patients with rheumatoid arthritis was followed by an open… 
1990
1990
Forty patients with active rheumatoid arthritis were included in this monocentre double-blind study comparing the therapeutic… 
Highly Cited
1989
Highly Cited
1989
A new immunomodulating drug, OM-8980, was compared to placebo in a 6-month double blind multicenter trial including 107 patients… 
1988
1988
  • T. Vischer
  • Annals of the Rheumatic Diseases
  • 1988
  • Corpus ID: 43261336
The therapeutic efficacy of the immunomodulator OM-8980 in rheumatoid arthritis was compared with that of auranofin, an oral gold…